stockrow
Friday 6 November 2026
Export VCYT’s income statement to Excel — free account
Veracyte, Inc.
VCYT Healthcare Diagnostics & Research
Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.
- Revenue
- +15.1%
- EPS
- +62.5%
- Free cash flow
- −9.63%
Quarter to September 2026, against a year earlier
24.19
0.19
+0.79%
Follow VCYT
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
28.96 | 40.78 | 29.02 | 50.12 |
+8 more quarters Free account |
P/S ratio |
6.37 | 8.36 | 4.73 | 6.40 | |
P/FCF ratio |
22.89 | 28.30 | 16.49 | 26.13 | |
P/Operating CF |
92.06 | 102.49 | 72.75 | 62.92 | |
P/B ratio |
2.59 | 3.38 | 1.91 | 2.53 | |
Price to Tangible BV |
9.44 | 8.72 | 5.21 | 7.30 | |
EV/Sales |
5.54 | 7.50 | 3.92 | 5.60 | |
EV/EBITDA |
26.01 | 34.00 | 22.14 | 38.17 | |
EV/Operating CF |
18.54 | 23.62 | 12.79 | 21.26 | |
EV/FCF |
19.90 | 25.39 | 13.68 | 22.88 | |
Quick Ratio |
0.67 | 8.60 | 8.72 | 7.63 | |
Current Ratio |
5.56 | 9.16 | 9.31 | 8.15 | |
Net Debt/EBITDA |
— | (17.91) | (15.99) | (9.87) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.40 | 0.40 | 0.39 | 0.38 | |
Operating CF/Net income |
1.28 | 1.80 | 1.23 | 1.28 | |
Capex/Depreciation |
0.00 | (0.69) | (0.61) | (0.81) | |
Research and Development Expense of Revenue |
21.19% | 19.59% | 19.49% | 14.82% | |
Selling, General and Administrative Expense of Revenue |
38.19% | 37.06% | 36.55% | 30.79% | |
Intangible Assets out of Total Assets |
0.66 | 0.57 | 0.59 | 0.61 | |
Share Based Compensation of Revenue |
9.20% | 9.37% | 9.18% | 7.75% | |
Graham Net Nets |
0.09 | 0.10 | 0.17 | 0.12 | |
Graham Number |
25.24 | 23.72 | 20.55 | 17.75 | |
Earnings Yield |
3.45% | 2.45% | 3.45% | 2.00% | |
Free Cash Flow Yield |
4.37% | 3.53% | 6.06% | 3.83% | |
Revenue per Share |
1.89 | 1.88 | 1.75 | 1.79 | |
Operating CF per Share |
0.50 | 0.57 | 0.44 | 0.67 | |
Capex per Share |
(0.03) | (0.04) | (0.04) | (0.05) | |
Free Cash Flow per Share |
0.47 | 0.54 | 0.41 | 0.62 | |
Cash per Share |
0.00 | 6.07 | 5.52 | 5.25 | |
Shareholders Equity per Share |
17.80 | 17.36 | 16.90 | 16.66 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.80 | 17.36 | 16.90 | 16.66 | |
Free Cash Flow |
37.92 | 42.97 | 32.25 | 48.80 | |
Working Capital |
383.67 | 512.04 | 466.06 | 428.44 | |
Capital Expenditures |
(2.33) | (2.86) | (2.96) | (3.78) | |
Net Current Asset Value |
327.89 | 476.81 | 430.18 | 391.93 | |
EV/EBIT |
32.43 | 39.84 | 27.41 | 50.15 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.03 | |
Price to Operating Income |
37.29 | 44.41 | 33.05 | 57.26 | |
| Other line items | |||||
Average Receivables |
52.31 | 52.50 | 51.95 | 45.59 | |
Average Payables |
7.61 | 9.74 | 11.31 | 6.61 | |
Average Inventory |
— | 23.84 | 22.84 | 21.15 | |
Average Assets |
1,470.52 | 1,415.24 | 1,375.91 | 1,353.03 | |
Average Common Equity |
1,345.47 | 1,304.73 | 1,269.67 | 1,242.77 |
Columns are period end dates · fundamentals updated 5 Nov 2026